Roles in PharmNovo: Chief executive officer, Business advisor and Director of the board.
Born: 1960.
Education: Bachelor’s degree in International Business Administration from the University of Lund.
Other current appointments: None.
Work experience: 30 years experience from International business in various industries and has vast experience in developing and transforming mid-size businesses. In 2003–2007 Per was VP Marketing & Sales for Nybron Flooring, European market leader in parquet flooring, with HQ in Switzerland and during 2008-2017 he was CEO at Elfa International with HQ in Malmö, Sweden.
Holdings: 25 000 shares.
Roles in PharmNovo: Founder, President, Chief scientific advisor and Director of the board.
Born: 1949.
Education: PhD in Zoophysiology, Medical Physiology/Pharmacology, Histology.
Other current appointments: None.
Work experience: AstraZeneca 30 years. Visiting Fellow at University of Leicester 1.5 years, University of Iowa and University of Boston 1.5 year. Employed at AZ at the departments of Physiology, Bioscience, Pharmacology and Molecular Pharmacology. Principal scientist, group leader in IBS pain Molecular Pharmacology.
Holdings: 652 000 shares.
Roles in PharmNovo: Chief scientific officer and Director of the board.
Born: 1954.
Education: Professor. Pharmacy graduate with a PhD in Neuropharmacology and worked as an industrial pharmacologist before returning to academic research at the Universities of Texas and Leicester.
Other current appointments: None.
Work experience: 30 years of Academic and Industrial Research. Until August 2015, he was Professor of Pharmacology and former Head of Biomedical Sciences at the University of Nottingham Medical School.
Holdings: 250 000 shares.
Role in PharmNovo: Global project lead.
Born: 1965
Education: MSc chemical engineering and PhD biotechology from Technical University of Denmark, BCom from Copenhagen Business School.
Other current appointments: None.
Work experience: Jesper is a very experienced pharma project leader with global experience across EU, US, China, Japan, and rest of world from early- as well as late-stage drug development projects and with significant experience from interactions with regulatory authorities such as EMA, FDA, PMDA, and CFDA.
For almost two decades, Jesper headed numerous global projects and large, global, cross-functional project teams at Lundbeck across the entire value chain and across small molecules and biologics. He was amongst others global project lead on successful development of Brintellix®/Trintellix® from pre-clinical development over phase I, II, and III clinical development and to registration and launch. Trintellix®/Brintellix® is today a globally launched blockbuster.
Holdings: None.
Roles in PharmNovo: Chemistry lead.
Born: 1959.
Education: B.Sc. in Chemistry and Ph.D. Preparative Organic Chemistry, Lund University. Associate Professor (docent) in Organic Pharmaceutical Chemistry, Uppsala University.
Other current appointments: None.
Work experience: Extensive experience from drug discovery and development and has held senior positions within a number of pharma and biotech companies, including AstraDraco, Acadia pharmaceuticals and KaroBio, where responsible for the chemical and pharmaceutical sciences and also intellectual property strategies. Associate professor of pharmaceutical chemistry and co-authored more than 100 scientific papers and patent applications.
Holdings: None.
Role in PharmNovo: Consultant and toxicology advisor.
Company: Toxicology Knowledge Team Sweden.
Resumé: Kerstin has a PhD from Karolinska Institutet, Stockholm. Her research background is within the area of cell biology and DNA repair. She has 16 years of experience from toxicology at Safety Assessment, AstraZeneca, working as toxicology project leader and study director for in vivo toxicology studies, and within molecular toxicology. During the last 8 years she has been working at Toxicology Knowledge Team Sweden as a consultant and cofounder.
Role in PharmNovo: Clinical outsourcing lead.
Company: WIN Outsourcing Consult.
Resumé: Rikke is highly specialized and globally experienced within Pre-clinical and Clinical R&D, Business Development and Contract/Outsourcing Management and has worked in the CRO and Pharmaceutical industry within these fields for more than 25 years.
For almost two decades, she headed up the R&D Outsourcing & Contracts Management R&D function at Lundbeck where she was globally responsible for all R&D outsourcing matters covering contractual, operational and relationship related activities with all CROs/vendors as well as complex research collaborations agreements with academia. Rikke has significant experience in developing and executing a broad variety of outsourcing strategies and is a strong negotiator with a win-win approach to retaining positive relationships with all stakeholders.
Prior to her employment at Lundbeck, Rikke worked for five years within bio-analytical research and clinical development in hospital/academia settings. This was followed by four years of employment in a larger CRO (International Project Manager followed by setting up the CRO’s first South East Asia office working as Business Development Manager and Line Manager in Singapore).
Rikke has since 2013 been a Steering Committee member of the Pharmaceutical Contract Management Group (PCMG.org.uk) in Europe.
Role in PharmNovo: Regulatory affairs Lead.
Company: Ozack ApS.
Resumé: Ann Christine Korsgaard has for 25 years + headed up Global Regulatory Functions as Vice President in companies like Shionogi in UK, UCB in Belgium, and Genmab, Action Pharma, Actavis, and LEO Pharma in Denmark. Ann Christine has been the Global Regulatory Lead on numerous projects and led companies through strategic value creating interactions and meetings with the Health Authorities in especially Europe, US and Japan.
The many regulatory opportunities have taken her from small to bigger companies, from small molecules to biological/biotech, from EU to Global, from research organizations to generics, from early development to post-marketing activities, from HQ to affiliates, from authorities to industry, and from working in Denmark to Norway, Belgium, and UK.
